Abstract
Engineered heart tissue patches might provide a future option for the therapy of terminal heart failure. Recent advantages in stem cell biology allow the generation of large numbers of human induced pluripotent stem cell derived cardiomyocytes (hiPS-CM). Here we investigated if human iPS-cell derived engineered heart tissue (hEHT) grafts support left ventricular function in infarcted hearts of guinea pigs, a species with a relatively human-like cardiac physiology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
